Novartis First MNC To Conduct Early Clinical Drug Trials In China
This article was originally published in PharmAsia News
Executive Summary
China FDA gave its first approval for a multinational pharma’s early clinical trial in China to Novartis’s lung cancer CMET kinase inhibitor, which the company plans to later apply to liver cancer treatment.